Online citations, reference lists, and bibliographies.
← Back to Search

Noninvasive Detection Of Clinically Occult Lymph-node Metastases In Prostate Cancer.

M. Harisinghani, J. Barentsz, P. Hahn, W. Deserno, S. Tabatabaei, Christine Hulsbergen van de Kaa, J. de la Rosette, R. Weissleder
Published 2003 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Accurate detection of lymph-node metastases in prostate cancer is an essential component of the approach to treatment. We investigated whether highly lymphotropic superparamagnetic nanoparticles, which gain access to lymph nodes by means of interstitial-lymphatic fluid transport, could be used in conjunction with high-resolution magnetic resonance imaging (MRI) to reveal small nodal metastases. METHODS Eighty patients with presurgical clinical stage T1, T2, or T3 prostate cancer who underwent surgical lymph-node resection or biopsy were enrolled. All patients were examined by MRI before and 24 hours after the intravenous administration of lymphotropic superparamagnetic nanoparticles (2.6 mg of iron per kilogram of body weight). The imaging results were correlated with histopathological findings. RESULTS Of the 334 lymph nodes that underwent resection or biopsy, 63 (18.9 percent) from 33 patients (41 percent) had histopathologically detected metastases. Of these 63 nodes, 45 (71.4 percent) did not fulfill the usual imaging criteria for malignancy. MRI with lymphotropic superparamagnetic nanoparticles correctly identified all patients with nodal metastases, and a node-by-node analysis had a significantly higher sensitivity than conventional MRI (90.5 percent vs. 35.4 percent, P<0.001) or nomograms. CONCLUSIONS High-resolution MRI with magnetic nanoparticles allows the detection of small and otherwise undetectable lymph-node metastases in patients with prostate cancer.
This paper references
10.1148/RADIOLOGY.162.2.3797645
Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging.
H. Hricak (1987)
10.1002/mrm.10068
Detection of lymph node metastases by contrast‐enhanced MRI in an experimental model
P. Wunderbaldinger (2002)
10.2307/2529310
The measurement of observer agreement for categorical data.
J. Landis (1977)
10.1056/NEJMOA010845
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
M. Smith (2001)
10.1161/01.CIR.103.3.415
Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits
S. Ruehm (2001)
10.1002/MRM.1910290504
Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties
T. Shen (1993)
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
P. Walsh (2000)
Vari - ations in morbidity after radical prostatectomy
T Shen (2002)
10.2214/AJR.172.5.10227514
MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation.
M. Harisinghani (1999)
10.1016/S0022-5347(01)61701-4
Bilateral Orchiectomy With or Without Flutamide for Metastatic Prostate Cancer
M. Eisenberger (1999)
10.1002/jmri.10134
Axillary lymph node metastases: A statistical analysis of various parameters in MRI with USPIO
C. Stets (2002)
10.1097/00000478-200111000-00012
Incidence, Location, and Significance of Periprostatic and Periseminal Vesicle Lymph Nodes in Prostate Cancer
P. S. Kothari (2001)
10.1148/RADIOL.2252011605
Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement.
S. C. Michel (2002)
10.1001/JAMA.285.5.562
Advances in biomedical imaging.
C. Tempany (2001)
10.1097/01.rli.0000135980.08491.33
Macrophage Imaging in Central Nervous System and in Carotid Atherosclerotic Plaque Using Ultrasmall Superparamagnetic Iron Oxide in Magnetic Resonance Imaging
C. Corot (2004)
10.1038/74464
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells
M. Lewin (2000)
10.1016/S0302-2838(02)00129-X
Visualization of prostate cancer with 11C-choline positron emission tomography.
I. D. de Jong (2002)
10.1161/01.STR.0000131268.50418.b7
In Vivo Detection of Macrophages in Human Carotid Atheroma: Temporal Dependence of Ultrasmall Superparamagnetic Particles of Iron Oxide–Enhanced MRI
R. Trivedi (2004)
10.1148/RADIOLOGY.175.2.2326475
Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging.
R. Weissleder (1990)
10.1038/73219
In vivo magnetic resonance imaging of transgene expression
R. Weissleder (2000)
10.1016/S1278-3218(98)80023-1
[Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin].
B. Chauvet (1998)
10.1038/nbt720
Magnetic relaxation switches capable of sensing molecular interactions
J. M. Pérez (2002)
10.1002/1522-2586(200012)12:6<899::AID-JMRI13>3.0.CO;2-R
MR imaging of mediastinal lymph nodes: Evaluation using a superparamagnetic contrast agent
H. Pannu (2000)
10.1148/RADIOLOGY.192.3.7520182
Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer.
Y. Anzai (1994)
10.1016/S0090-4295(02)01531-5
Frozen section diagnosis of metastatic prostate adenocarcinoma in pelvic lymphadenectomy compared with nomogram prediction of metastasis.
R. Beissner (2002)
10.1016/S0033-8389(05)70152-4
The prostate: MR imaging and spectroscopy. Present and future.
J. Kurhanewicz (2000)
10.1056/NEJM199108153250701
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.
H. Barnett (1991)
10.1056/NEJMSA011788
Variations in morbidity after radical prostatectomy.
C. Begg (2002)
10.1038/76194
Prostate cancer schemes for androgen escape
Albert O. Brinkmann (2000)
10.1001/JAMA.1997.03540420041027
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
A. Partin (1997)
10.1161/01.CIR.92.5.1355
A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.
H. Stary (1995)
10.1016/S0090-4295(99)80219-2
Open pelvic lymph node dissection for prostate cancer: a reassessment.
S. Campbell (1995)
10.1002/mrm.10418
Cell internalization of anionic maghemite nanoparticles: Quantitative effect on magnetic resonance imaging
C. Billotey (2003)
Imaging macrophage activity in the brain by using ultrasmall particles of iron oxide.
J. Bulte (2000)
10.1016/S0094-0143(05)70157-9
Indications for pelvic lymphadenectomy in prostate cancer.
R. Link (2001)
10.1097/00004424-198609000-00009
ROC Methodology in Radiologic Imaging
C. Metz (1986)
10.1056/NEJM200103083441017
MRI-guided diagnosis and treatment of prostate cancer.
A. D'Amico (2001)
10.1097/00000478-199812000-00006
Cancer volume of lymph node metastasis predicts progression in prostate cancer.
L. Cheng (1998)
10.1016/s0003-3944(02)00904-5
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.
P. Walsh (2003)
10.1056/NEJMOA012794
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.
L. Holmberg (2002)
10.1056/NEJME020089
Surgery and the reduction of mortality from prostate cancer.
P. Walsh (2002)
10.2214/AJR.167.6.8956585
Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence.
G. Jager (1996)
10.1093/JNCI/94.16.1197
Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions.
R. Katz-Brull (2002)
10.3322/canjclin.51.1.15
Cancer Statistics, 2001
R. Greenlee (2001)



This paper is referenced by
10.2174/9781608058846114030010
Theranostic Metallic Nanomedicine in Oncology: New Insights and Concerns
S. Akhter (2014)
10.1021/acs.molpharmaceut.7b00890
Nanoparticles with CD44 Targeting and ROS Triggering Properties as Effective in Vivo Antigen Delivery System.
X. Liang (2018)
Molecular genetic predictors of prostate cancer progression after radical prostatectomy.
S. Bott (2006)
10.1007/s00120-010-2271-2
Lymphknotenmetastasendiagnostik bei urologischen Tumoren
M. Seitz (2010)
MR molecular imaging of angiogenesis using targeted perfluorocarbon nanoparticles.
S. Caruthers (2010)
10.1016/J.RCL.2004.07.004
MR techniques for in vivo molecular and cellular imaging.
E. Delikatny (2005)
10.1038/nrcardio.2009.119
Molecular imaging in cardiovascular disease: targets and opportunities
S. Shaw (2009)
10.2214/AJR.08.2175
Lymphotropic nanoparticle-enhanced MRI for independent prediction of lymph node malignancy: a logistic regression model.
P. Pandharipande (2009)
Decontamination of surfaces exposed to single wall carbon nanohorns
Z. Karimia (2016)
RNA Nanodrug Image-Guided Breast Tumor Therapy Using a Small Interfering
M. Kumar (2010)
10.7150/THNO.32362
Strategies for Image-Guided Therapy, Surgery, and Drug Delivery Using Photoacoustic Imaging
Colman Moore (2019)
10.1016/j.radonc.2011.05.005
Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer.
M. Souvatzoglou (2011)
10.1002/jso.21794
Experimental models to study lymphatic and blood vascular metastasis
L. Chen (2011)
10.1159/000099026
Role of Preoperative Local and Distant Staging in Rectal Cancer
S. M. Engelen (2007)
Conception et synthese de nouvelles sondes ciblees pour l'imagerie moleculaire
Claire Beauvineau (2011)
10.2214/AJR.05.0873
Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers.
M. Saksena (2006)
10.1097/01.RLI.0000262759.46364.50
Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy.
S. Heijmink (2007)
10.1227/01.NEU.0000255350.71700.37
THE POTENTIAL OF FERUMOXYTOL NANOPARTICLE MAGNETIC RESONANCE IMAGING, PERFUSION, AND ANGIOGRAPHY IN CENTRAL NERVOUS SYSTEM MALIGNANCY: A PILOT STUDY
E. Neuwelt (2007)
10.1007/s00259-004-1542-9
Is 11C-choline the most appropriate tracer for prostate cancer?
F. Fazio (2004)
10.1200/JCO.2006.06.6159
New technologies and directed agents for applications of cancer imaging.
M. Atri (2006)
10.1038/ncpuro0452
Technology Insight: monoclonal antibody imaging of prostate cancer
N. Bander (2006)
10.1016/j.juro.2011.07.046
The role of magnetic resonance imaging in the detection of prostate cancer.
Seungtaek Choi (2011)
10.1172/JCI71612
Emerging lymphatic imaging technologies for mouse and man.
E. Sevick-Muraca (2014)
10.4018/978-1-5225-4781-5.CH007
Magnetic Nano-Systems in Drug Delivery and Biomedical Applications
Saritha Shetty (2018)
10.1182/BLOOD.V108.11.3944.3944
In Vitro Characterization of Magnetic Resonance Imaging Contrast Agents for Molecular Imaging.
Z. Yu (2006)
10.5173/ceju.2018.1478
Extended robotic salvage lymphadenectomy in patients with ‘node-only’ prostate cancer recurrence: initial experience
K. Kolontarev (2018)
10.1097/JU.0000000000000295
Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.
T. Pisansky (2019)
10.1055/s-0028-1098914
[First results of PET / CT-guided secondary lymph node surgery on patients with a PSA relapse after radical prostatectomy].
A. Winter (2009)
International Journal of Nanomedicine
Mitsuhiro Terakawa ()
10.3109/9781420016635-12
Magnetic Resonance Imaging of the Prostate Gland
Saroja Adusumilli (2006)
10.1002/bjs.5920
Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer
T. Noji (2008)
Magnetic Resonance Imaging in the management of prostate cancer: What the Radiologists need to know?
Sneha Deshpande (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar